Physician profile
Brad C Erikson
NPI 1164477931
$7,030.95
in general payments reported to CMS, 2019-2025
51 companies · $1,439 in 2025
The $1,439 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $680 · 2020: $831 · 2021: $1,279 · 2022: $917 · 2023: $894 · 2024: $991 · 2025: $1,439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,323.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,507.42 | 2021-2025 | |
| Lilly USA, LLC | $617.30 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $551.32 | 2019-2023 | Veozah |
| Astrazeneca Pharmaceuticals LP | $482.69 | 2019-2024 | Farxiga |
| Glaxosmithkline, LLC. | $405.95 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Amgen INC. | $316.50 | 2019-2025 | Evenity, Prolia, Prolia |
| Otsuka America Pharmaceutical, INC. | $294.22 | 2019-2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $290.26 | 2024-2025 | Fanapt |
| Novo Nordisk INC | $270.85 | 2019-2025 | Ozempic, Rybelsus |
| Axsome Therapeutics, INC. | $213.81 | 2022-2025 | Auvelity, Sunosi |
| Allergan, INC. | $188.61 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $188.46 | 2022-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $139.14 | 2024-2025 | Voquezna |
| Pfizer INC. | $134.82 | 2020-2025 | |
| Xeris Pharmaceuticals, INC. | $120.04 | 2023-2024 | Gvoke Hypopen |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Erikson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.